Biotech Values

[dav1234]

Cantor raises price target on Celldex
Cantor Fitzgerald follows Leerink in hiking the price target on Celldex Therapeutics (CLDX) after the stock's recent move higher.Once the shares rose above Cantor's previous target ($24), analyst Mara Goldstein knew just what to do: "Shares have experienced strength of late [and] we like CLDX's pipeline and the opportunity for continued valuation expansion based on catalyst events. Using a risk-adjusted revenue calculation of each [pipeline] candidate, plus the value of technology, early-stage assets, and cash, we see upside to $39."The new target represents a 19% upside from Monday's close.



It may very well be a " dud"..but its been great for the longs( not me unfortunately)